Stay informed with the latest litigation news. Explore now

Mitsubishi Tanabe Pharma competitive analysis

Latest publications and patents of Mitsubishi Tanabe Pharma New

Explore the latest publications and patents granted to Mitsubishi Tanabe Pharma, showcasing their recent innovations and technological advancements.

Last updated on: Sep 6, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Mitsubishi Tanabe Pharma

May 7, 2025Composition And Method For Evaluating Responsiveness Of EdaravoneRequest For Examination Was Made
Jun 19, 2024Edaravone Suspension For Oral AdministrationGranted And Under Opposition
Oct 7, 2020Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose TransporterPatent Maintained As Amended
Oct 23, 2019Combination Therapy Comprising Sglt Inhibitors And Dpp4 InhibitorsRevoked
Apr 3, 2019Medicinal Agent For Treating Amyotrophic Lateral Sclerosis Or Preventing Progression Of Phase Of Amyotrophic Lateral SclerosisRevoked
Mar 28, 2018Novel Therapeutic Agent For Amyotrophic Lateral Sclerosis (Als) Or Disease Attributable To AlsRevoked
Jan 31, 2018Novel Renin InhibitorNo Opposition Filed Within Time Limit
Jan 17, 2018Amine Compound And Use Thereof For Medical PurposesNo Opposition Filed Within Time Limit
Jan 3, 2018Rotavirus-Like Particle Production In PlantsNo Opposition Filed Within Time Limit

Explore Mitsubishi Tanabe Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 11, 2025
Patent NumberGrant DateTitleTotal Oppositions
Jun 19, 2024Edaravone Suspension For Oral Administration1
Oct 7, 2020Novel Compounds Having Inhibitory Activity Against Sodium-Dependant Glucose Transporter2
Oct 23, 2019Combination Therapy Comprising Sglt Inhibitors And Dpp4 Inhibitors1
Apr 3, 2019Medicinal Agent For Treating Amyotrophic Lateral Sclerosis Or Preventing Progression Of Phase Of Amyotrophic Lateral Sclerosis1
Mar 28, 2018Novel Therapeutic Agent For Amyotrophic Lateral Sclerosis (Als) Or Disease Attributable To Als1

Latest PTAB cases involving Mitsubishi Tanabe Pharma New

Discover the latest PTAB cases involving Mitsubishi Tanabe Pharma, highlighting their recent legal challenges and patent disputes.

Top competitors of Mitsubishi Tanabe Pharma

Top competitors of Mitsubishi Tanabe Pharma based on patent oppositions.